Application of aerosol therapy in respiratory diseases in children: A Saudi expert consensus

Adel S Alharbi, Abdullah A Yousef, Saleh A Alharbi, Abdullah Al-Shamrani, Mansour M Alqwaiee, Mohammed Almeziny, Yazan S Said, Saleh Ali Alshehri, Faisal N Alotaibi, Rafat Mosalli, Khaled Ali Alawam, Muslim M Alsaadi, Adel S Alharbi, Abdullah A Yousef, Saleh A Alharbi, Abdullah Al-Shamrani, Mansour M Alqwaiee, Mohammed Almeziny, Yazan S Said, Saleh Ali Alshehri, Faisal N Alotaibi, Rafat Mosalli, Khaled Ali Alawam, Muslim M Alsaadi

Abstract

The Saudi Pediatric Pulmonology Association (SPPA) is a subsidiary of the Saudi Thoracic Society (STS), which consists of a group of Saudi experts with well-respected academic and clinical backgrounds in the fields of asthma and other respiratory diseases. The SPPA Expert Panel realized the need to draw up a clear, simple to understand, and easy to use guidance regarding the application of different aerosol therapies in respiratory diseases in children, due to the high prevalence and high economic burden of these diseases in Saudi Arabia. This statement was developed based on the available literature, new evidence, and experts' practice to come up with such consensuses about the usage of different aerosol therapies for the management of respiratory diseases in children (asthma and nonasthma) in different patient settings, including outpatient, emergency room, intensive care unit, and inpatient settings. For this purpose, SPPA has initiated and formed a national committee which consists of experts from concerned specialties (pediatric pulmonology, pediatric emergency, clinical pharmacology, pediatric respiratory therapy, as well as pediatric and neonatal intensive care). These committee members are from different healthcare sectors in Saudi Arabia (Ministry of Health, Ministry of Defence, Ministry of Education, and private healthcare sector). In addition to that, this committee is representing different regions in Saudi Arabia (Eastern, Central, and Western region). The subject was divided into several topics which were then assigned to at least two experts. The authors searched the literature according to their own strategies without central literature review. To achieve consensus, draft reports and recommendations were reviewed and voted on by the whole panel.

Keywords: Aerosol therapy; Saudi Arabia; children; consensus.

Conflict of interest statement

The committee is fully sponsored by the Saudi Thoracic Society.

Copyright: © 2021 Annals of Thoracic Medicine.

Figures

Figure 1
Figure 1
Structure of a jet nebulizer
Figure 2
Figure 2
Structure of an ultrasonic nebulizer
Figure 3
Figure 3
Structure of a vibrating mesh nebulizer
Figure 4
Figure 4
Illustration of particle transport onto airway surfaces
Figure 5
Figure 5
Fate of inhaled drug
Figure 6
Figure 6
A schematic diagram of the pressurized metered dose inhaler
Figure 7
Figure 7
Choice of delivery device in children of different ages

References

    1. Mulholland K. Global burden of acute respiratory infections in children: Implications for interventions. Pediatr Pulmonol. 2003;36:469–74.
    1. Alsubaiei ME, Cafarella PA, Frith PA, McEvoy RD, Effing TW. Factors influencing management of chronic respiratory diseases in general and chronic obstructive pulmonary disease in particular in Saudi Arabia: An overview. Ann Thorac Med. 2018;13:144–149. doi: 10.4103/atm.ATM_293_17. PMID: 30123332; PMCID: PMC6073786.
    1. Al Frayh AR, Shakoor Z, Gad El Rab MO, Hasnain SM. Increased prevalence of asthma in Saudi Arabia. Ann Allergy Asthma Immunol. 2001;86:292–6.
    1. DiBlasi RM. Clinical controversies in aerosol therapy for infants and children. Respir Care. 2015;60:894–914.
    1. The Edwin Smith Surgical Papyrus: Published in Facsimile and Hieroglyphic Transliteration with Translation and Commentary in Two Volumes. JAMA: The Journal of the American Medical Association. 1931;96:1534.
    1. Heydari M, Hashempur MH, Zargaran A. Medicinal aspects of opium as described in Avicenna's Canon of Medicine. Acta Med Hist Adriat. 2013;11:101–12.
    1. Sanders M. Inhalation therapy: An historical review. Prim Care Respir J. 2007;16:71–81.
    1. Anderson PJ. History of aerosol therapy: Liquid nebulization to MDIs to DPIs. Respir Care. 2005;50:1139–50.
    1. Shehata M. History of inhalation therapy. Internet J Health. 2008;9:1–9.
    1. Lee MR. The history of Ephedra (Ma-Huang) J R Coll Physicians Edinb. 2011;41:78–84.
    1. Viswanathan R. Historical aspects of bronchial asthma. Indian J Chest Dis. 1964;6:165–9.
    1. Brenner BE. Where have we been? The history of acute asthma. In: Brenner BE, editor. Emergency Asthma. New York: Marcel Dekker, Inc; 1999. pp. 1–32.
    1. Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J. 1975;51:13–20.
    1. Mudge J. A Radical and Expeditious Cure for a Recent Catarrhous Cough. 2nd ed. London: E Allen; 1778. pp. 131–47.
    1. Warren I. Boston: Higgins, Bradley, and Dayton; 1989. The Household Physician: For the Use of Families, Planters, Seamen, and Travellers.
    1. Bleyer JM. A new method of laryngeal and bronchial medication by means of a spray and tube during the act of deep inspiration: Read in the Section of Laryngology and Otology at the Forty-First Annual Meeting of the American Medical Association, Nashville, Tenn, May, 1890. J Am Med Assoc. 1890;15:634–6.
    1. Wyeth J. Philadelphia, PA: John Wyeth & Brother, Inc; 1901. An Epitome of Therapeutics with Special Reference to the Laboratory Products of John Wyeth and Brother; pp. 251–2.
    1. Nikander K, Sanders M. The early evolution of nebulizers. Medicamundi. 2010;54:47–53.
    1. Abramson HA. Principles and, practice of aerosol therapy of the lungs and bronchi. Ann Allergy. 1946;4:440–56.
    1. Rau JL. The inhalation of drugs: Advantages and problems. Respir Care. 2005;50:367–82.
    1. Kacmarek R, Stoller J, Heuer A. 12th ed. Elsevier Health Sciences; 2020. Egan's Fundamentals of Respiratory Care [Internet] Available from: . Last cited on 2021 Mar 24.
    1. Gardenhire D. Rau's Respiratory Care Pharmacology E-book [Internet] 9th ed. Elsevier Health Sciences; 2015. Available from: . Last cited on 2021 Mar 24.
    1. Mosby's Respiratory Care Equipment E-book [Internet] 10th ed. Elsevier Health Sciences; 2017. Available from: . Last cited on 2021 Mar 24.
    1. Nerbrink O, Dahlbäck M, Hansson HC. Why do medical nebulizers differ in their output and particle size characteristics. J Aerosol Med. 1994;7:259–76.
    1. Gardenhire DS, Burnett D, Strickland S, Myers TR. A Guide to Aerosol Delivery Devices for Respiratory Therapists. 4th ed. Irving, Texas: American Association for Respiratory Care; 2017.
    1. Goode ML, Fink JB, Dhand R, Tobin MJ. Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am J Respir Crit Care Med. 2001;163:109–14.
    1. Phipps PR, Gonda I. Droplets produced by medical nebulizers Some factors affecting their size and solute concentration. Chest. 1990;97:1327–32.
    1. De Benedictis FM, Selvaggio D. Use of inhaler devices in pediatric asthma. Paediatr Drugs. 2003;5:629–38.
    1. Yeo LY, Friend JR, McIntosh MP, Meeusen EN, Morton DA. Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opin Drug Deliv. 2010;7:663–79.
    1. Thomas SH, O’Doherty MJ, Page CJ, Treacher DF, Nunan TO. Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation. Am Rev Respir Dis. 1993;148:872–7.
    1. Michotte JB, Jossen E, Roeseler J, Liistro G, Reychler G. In vitro comparison of five nebulizers during noninvasive ventilation: Analysis of inhaled and lost doses. J Aerosol Med Pulm Drug Deliv. 2014;27:430–40.
    1. Dolovich MB, Dhand R. Aerosol drug delivery: Developments in device design and clinical use. Lancet. 2011;377:1032–45.
    1. Stuart BO. Deposition of inhaled aerosols. Arch Intern Med. 1973;131:60–73.
    1. Newman SP, Agnew JE, Pavia D, Clarke SW. Inhaled aerosols: Lung deposition and clinical applications. Clin Phys Physiol Meas. 1982;3:1–20.
    1. Bisgaard H, O’Callaghan C, Smaldone GC. New York: Marcel Dekker; 2002. Drug Delivery to the Lung; p. 162.
    1. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm. 2005;62:1359–64.
    1. Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol. 2001;51:289–99.
    1. Strong P, Ito K, Murray J, Rapeport G. Current approaches to the discovery of novel inhaled medicines. Drug Discov Today. 2018;23:1705–17.
    1. O’Connell EJ. Review of the unique properties of budesonide. Clin Ther. 2003;25(Suppl C):C42–60.
    1. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med. 1996;153:1636–40.
    1. Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7:1839–44.
    1. Derendorf H, Hochhaus G, Möllmann H. Evaluation of pulmonary absorption using pharmacokinetic methods. J Aerosol Med. 2001;14:9–17.
    1. Van Oort M. In vitro testing of dry powder inhalers. Aerosol Sci Technol. 1995;22:364–73.
    1. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50:1313–21.
    1. Newman SP. Principles of metered-dose inhaler design. Respir Care. 2005;50:1177–90.
    1. Mundy L, Sellvaraj U, Victoria N, Jotsingani N. Coping with Asthma. [Last accessed on 2020 Oct 04]. Available from: .
    1. Newman S, Pitcairn G, Steed K, Harrison A, Nagel J. Deposition of fenoterol from pressurized metered dose inhalers containing hydrofluoroalkanes. J Allergy Clin Immunol. 1999;104:S253-7.
    1. Newman SP, Woodman G, Clarke SW, Sackner MA. Effect of InspirEase on the deposition of metered-dose aerosols in the human respiratory tract. Chest. 1986;89:551–6.
    1. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: Deposition studies and clinical aspects. J Aerosol Med. 1996;9:55–70.
    1. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis. 1984;129:723–9.
    1. Kim CS, Eldridge MA, Sackner MA. Oropharyngeal deposition and delivery aspects of metered-dose inhaler aerosols. Am Rev Respir Dis. 1987;135:157–64.
    1. Wildhaber JH, Devadason SG, Hayden MJ, James R, Dufty AP, Fox RA, et al. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol. Eur Respir J. 1996;9:1943–6.
    1. Piérart F, Wildhaber JH, Vrancken I, Devadason SG, Le Souëf PN. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J. 1999;13:673–8.
    1. Wildhaber JH, Devadason SG, Eber E, Hayden MJ, Everard ML, Summers QA, et al. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax. 1996;51:985–8.
    1. British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax. 2008;63(Suppl 4) iv1-121. doi: 10.1136/thx.2008.097741. PMID: 18463203.
    1. Cates CJ, Crilly JA, Rowe BH. Cochrane Database Syst Rev. 2006. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma; p. CD000052. doi: 10.1002/14651858.CD000052.pub2. Update in: Cochrane Database Syst Rev. 2013;9:CD000052. PMID: 16625527.
    1. Dubus JC, Mély L, Huiart L, Marguet C, Le Roux P Réseau de Recherche Clinique en Pneumologie Pédiatrique. Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma. Fundam Clin Pharmacol. 2003;17:627–31.
    1. Al-Moamary MS, Alhaider SA, Alangari AA, Al Ghobain MO, Zeitouni MO, Idrees MM, et al. The Saudi Initiative for Asthma – 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med. 2019;14:3–48.
    1. Amirav I, Newhouse MT, Minocchieri S, Castro-Rodriguez JA, Schüepp KG. Factors that affect the efficacy of inhaled corticosteroids for infants and young children. J Allergy Clin Immunol. 2010;125:1206–11.
    1. Khilnani GC, Banga A. Aerosol therapy. Indian J Chest Dis Allied Sci. 2008;50:209.
    1. Rubin BK, Fink JB. Aerosol therapy for children. Respir Care Clin N Am. 2001;7:175.
    1. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335–71.
    1. Chipps BE, Bacharier LB, Farrar JR, Jackson DJ, Murphy KR, Phipatanakul W, et al. The pediatric asthma yardstick: Practical recommendations for a sustained step-up in asthma therapy for children with inadequately controlled asthma. Ann Allergy Asthma Immunol. 2018;120:559–79.e11.
    1. Rubin BK. Pediatric aerosol therapy: New devices and new drugs. Respir Care. 2011;56:1411–21.
    1. Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC, et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2011 Jun;15(6):CD003123. doi: 10.1002/14651858.CD003123.pub3. PMID: 21678340.
    1. Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med. 2009;360:2079–89.
    1. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2008 Oct;8(4):CD006458. doi: 10.1002/14651858.CD006458.pub2. Update in: Cochrane Database Syst Rev. 2013;7:CD006458. PMID: 18843717.
    1. Umoren R, Odey F, Meremikwu MM. Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age. Cochrane Database Syst Rev. 2011 Jan;19(1):CD006435. doi: 10.1002/14651858.CD006435.pub2. PMID: 21249676.
    1. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol. 1998;25:88–92.
    1. Jensen T, Pederson SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987;19:831–8.
    1. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20:658–64.
    1. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2008;21:71–6.
    1. Ring E, Eber E, Erwa W, Zach M S. Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation. Arch Dis Child. 1998;78:540–3.
    1. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340:23–30.
    1. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol. 1989;7:265–71.
    1. Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM. Acute renal failure in cystic fibrosis: Association with inhaled tobramycin therapy. Pediatr Pulmonol. 2002;34:375–7.
    1. Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respir Care. 2007;52:859–65.
    1. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–40.
    1. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: A randomised trial. Lancet. 2001;358:1316–21.
    1. Wills PJ. Inhaled mannitol in cystic fibrosis. Expert Opin Investig Drugs. 2007;16:1121–6.
    1. Murgia X, Gastiasoro E, Mielgo V, Alvarez-Diaz F, Lafuente H, Valls-i-Soler A, et al. Surfactant and perfluorocarbon aerosolization by means of inhalation catheters for the treatment of respiratory distress syndrome: An in vitro study. J Aerosol Med Pulm Drug Deliv. 2011;24:81–7.
    1. Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, et al. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J. 2009;34:354–60.
    1. Snyder AH, McPherson ME, Hunt JF, Johnson M, Stamler JS, Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med. 2002;165:922–6.
    1. Eckstein JW, Fung J. A new class of cyclosporin analogues for the treatment of asthma. Expert Opin Investig Drugs. 2003;12:647–53.
    1. Groves S, Galazka M, Johnson B, Corcoran T, Verceles A, Britt E, et al. Inhaled cyclosporine and pulmonary function in lung transplant recipients. J Aerosol Med Pulm Drug Deliv. 2010;23:31–9.
    1. Amirav I, Newhouse MT. Aerosol therapy in tracheotomized children: Time for guidelines! Respir Care. 2012;57:1350.
    1. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52:1176–93.
    1. Brightling CE. Clinical applications of induced sputum. Chest. 2006;129:1344–8.
    1. Elkins MR, Bye PT. Mechanisms and applications of hypertonic saline. J R Soc Med. 2011;104:S2-5.
    1. Bennett WD, Wu J, Fuller F, Balcazar JR, Zeman KL, Duckworth H, et al. Duration of action of hypertonic saline on mucociliary clearance in the normal lung. J Appl Physiol. 2015;118:1483–90.
    1. Bateman ED, Rennard S, Barnes PJ, Dicpinigaitis PV, Gosens R, Gross NJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther. 2009;22:533–42.
    1. Tagaya E, Yagi O, Sato A, Arimura K, Takeyama K, Kondo M, et al. Effect of tiotropium on mucus hypersecretion and airway clearance in patients with COPD. Pulm Pharmacol Ther. 2016;39:81–4.
    1. Blasco PA, Stansbury JC. Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med. 1996;150:932–5.
    1. Garnock-Jones KP. Glycopyrrolate oral solution: For chronic, severe drooling in pediatric patients with neurologic conditions. Paediatr Drugs. 2012;14:263–9.
    1. Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord. 2007;22:2268–73.
    1. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: A double-blind, dose ranging study. Arch Pediatr Adolesc Med. 2000;154:1214–8.
    1. Ahrens RC. The role of the MDI and DPI in pediatric patients: Children are not just miniature adults. Respir Care. 2005;50:1323–8.
    1. Bhashyam AR, Wolf MT, Marcinkowski AL, Saville A, Thomas K, Carcillo JA, et al. Aerosol delivery through nasal cannulas: An in vitro study. J Aerosol Med Pulm Drug Deliv. 2008;21:181–8.
    1. Lin HL, Restrepo RD, Gardenhire DS, Rau JL. Effect of face mask design on inhaled mass of nebulized albuterol, using a pediatric breathing model. Respir Care. 2007;52:1021–6.
    1. Everard ML. Trying to deliver aerosols to upset children is a thankless task. Arch Dis Child. 2000;82:428.
    1. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2007. Aug, [Last accessed on 2021 Mar 24]. Available from:
    1. Ari A, Fink JB. Guidelines for aerosol devices in infants, children and adults: which to choose, why and how to achieve effective aerosol therapy. Expert Rev Respir Med. 2011;5:561–72.
    1. Choi J, Lee GL. Common pediatric respiratory emergencies. Emerg Med Clin North Am. 2012;30:529–63.
    1. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–8.
    1. Chinese College of Emergency Physicians (CCEP), Emergency Committee of PLA, Beijing Society for Emergency Medicine, Chinese Emergency Medicine. Expert consensus on nebulization therapy in pre-hospital and in-hospital emergency care. Ann Transl Med. 2019;7:487.
    1. Sawicki G, Haver K. Acute asthma exacerbations in children younger than 12 years: Home/office management and severity assessment. U: UpToDate. In: TePas E, editor. UpToDate. Waltham, MA: UpToDate; 2020. [Last accessed on 2020 Jun 15]. Available from: .
    1. Network British Guideline. British Guideline on the Management of Asthma. 2019. [Last accessed on 2020 Oct 20]. Available from:
    1. Plotnick LH, Ducharme FM. Cochrane Database Syst Rev. 4. 2000. Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children; p. CD000060. doi: 10.1002/14651858.CD000060. Update in: Cochrane Database Syst Rev. 2013;8:CD000060. PMID: 11034671.
    1. Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med. 1998;339:1030–5.
    1. Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med. 1993;21:1479–86.
    1. Katz RW, Kelly HW, Crowley MR, Grad R, McWilliams BC, Murphy SJ. Safety of continuous nebulized albuterol for bronchospasm in infants and children. Pediatrics. 1993;92:666–9.
    1. McPeck M, Tandon R, Hughes K, Smaldone GC. Aerosol delivery during continuous nebulization. Chest. 1997;111:1200–5.
    1. Manjra AI, Price J, Lenney W, Hughes S, Barnacle H. Efficacyof nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma. Respir Med. 2000;94:1206–14.
    1. Matthews EE, Curtis PD, McLain BI, Morris LS, Turbitt ML. Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr. 1999;88:841–3.
    1. Volovitz B, Bentur L, Finkelstein Y, Mansour Y, Shalitin S, Nussinovitch M, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: A controlled comparative study with oral prednisolone. J Allergy Clin Immunol. 1998;102:605–9.
    1. Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. 2018. [last accessed on 2021 Mar 24]. Available from: .
    1. Management of Acute Asthma Exacerbations in the Emergency Department and Hospital-Based Care. A consensus statement of the Egyptian Scientific Society of Bronchology (ESSB) [Internet]. ESSB. 2015. Available from: . last cited on 2021 Mar 24.
    1. Geppe NA, et al. Ros Vestn Perinatoli Pediatr. 2018;63(3):125–132. in Russ. doi: 10.21508/1027-4065-2018-63-3-125-132.
    1. Fok TF, Monkman S, Dolovich M, Gray S, Coates G, Paes B, et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 1996;21:301–9.
    1. Lin YZ, Hsieh KH. Metered dose inhaler and nebuliser in acute asthma. Arch Dis Child. 1995;72:214–8. doi: 10.1136/adc.72.3.214. PMID: 7741566. PMCID: PMC1511067.
    1. Deerojanawong J, Manuyakorn W, Prapphal N, Harnruthakorn C, Sritippayawan S, Samransamruajkit R. Randomized controlled trial of salbutamol aerosol therapy via metered dose inhaler-spacer vs. jet nebulizer in young children with wheezing. Pediatr Pulmonol. 2005;39:466–72.
    1. Leversha AM, Campanella SG, Aickin RP, Asher MI. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. J Pediatr. 2000;136:497–502.
    1. Wildhaber JH, Devadason SG, Hayden MJ, Eber E, Summers QA, LeSouëf PN. Aerosol delivery to wheezy infants: A comparison between a nebulizer and two small volume spacers. Pediatr Pulmonol. 1997;23:212–6.
    1. Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: A double-blind study. Am J Dis Child. 1978;132:484–7.
    1. Bjornson C, Russell KF, Vandermeer B, Durec T, Klassen TP, Johnson DW. Nebulized epinephrine for croup in children. Cochrane Database Syst Rev. 2011 Feb;16(2):CD006619. doi: 10.1002/14651858.CD006619.pub2. Update in: Cochrane Database Syst Rev. 2013;10:CD006619. PMID: 21328284.
    1. Lee JH, Jung JY, Lee HJ, Kim DK, Kwak YH, Chang I, et al. Efficacy of low-dose nebulized epinephrine as treatment for croup: A randomized, placebo-controlled, double-blind trial. Am J Emerg Med. 2019;37:2171–6.
    1. Waisman Y, Klein BL, Boenning DA, Young GM, Chamberlain JM, O’Donnell R, et al. Prospective randomized double-blind study comparing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup) Pediatrics. 1992;89:302–6.
    1. Moore M, Little P Humidified air inhalation for treating croup. Cochrane Database Syst Rev. 2006 Jul;19(3):CD002870. doi: 10.1002/14651858.CD002870.pub2. Update in: Cochrane Database Syst Rev. 2011;(6):CD002870. PMID: 16855994.
    1. Henrickson KJ. Advances in the laboratory diagnosis of viral respiratory disease. Pediatr Infect Dis J. 2004;23:S6-10.
    1. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588–98.
    1. Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcuse E, Zerr DM. Variation in inpatient diagnostic testing and management of bronchiolitis. Pediatrics. 2005;115:878–84.
    1. Eboriadou M, Chryssanthopoulou D, Stamoulis P, Damianidou L, Haidopoulou K. The effectiveness of local corticosteroids therapy in the management of mild to moderate viral croup. Minerva Pediatr. 2010;62:23–8.
    1. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014 Jun;17 2014(6):CD001266. doi: 10.1002/14651858.CD001266.pub4. PMID: 24937099. PMCID: PMC7055016.
    1. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. American Academy of Pediatrics Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134:e1474–502.
    1. Alharbi AS, Alqwaiee M, Al-Hindi MY, Mosalli R, Al-Shamrani A, Alharbi S, et al. Bronchiolitis in children: The Saudi Initiative of Bronchiolitis Diagnosis, Management, and Prevention (SIBRO) Ann Thorac Med. 2018;13:127–43.
    1. Panitch HB. Respiratory syncytial virus bronchiolitis: Supportive care and therapies designed to overcome airway obstruction. Pediatr Infect Dis J. 2003;22:S83-7.
    1. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134:e1474–502.
    1. Cade A, Brownlee KG, Conway SP, Haigh D, Short A, Brown J, et al. Randomised placebo controlled trial of nebulized corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child. 2000;82:126–30.
    1. Blom D, Ermers M, Bont L, van Aalderen WM, van Woensel JB. Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. Cochrane Database Syst Rev. 2007 Jan;24(1):CD004881. doi: 10.1002/14651858.CD004881.pub2. Update in: Cochrane Database Syst Rev. 2011;(1):CD004881. PMID: 17253528.
    1. Dhand R. Inhalation therapy in invasive and noninvasive mechanical ventilation. Curr Opin Crit Care. 2007;13:27–38.
    1. Dhanani J, Fraser JF, Chan HK, Rello J, Cohen J, Roberts JA. Fundamentals of aerosol therapy in critical care. Crit Care. 2016;20:269.
    1. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372:2185–96.
    1. Hess DR. Aerosol therapy during noninvasive ventilation or high-flow nasal cannula. Respir Care. 2015;60:880–91.
    1. Cabrini L, Landoni G, Oriani A, Plumari VP, Nobile L, Greco M, et al. Noninvasive ventilation and survival in acute care settings: A comprehensive systematic review and metaanalysis of randomized controlled trials. Crit Care Med. 2015;43:880–8.
    1. Nava S, Karakurt S, Rampulla C, Braschi A, Fanfulla F. Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: A randomized, controlled study. Intensive Care Med. 2001;27:1627–35.
    1. Galindo-Filho VC, Brandão DC, Ferreira Rde C, Menezes MJ, Almeida-Filho P, Parreira VF, et al. Noninvasive ventilation coupled with nebulization during asthma crises: A randomized controlled trial. Respir Care. 2013;58:241–9.
    1. Gupta D, Nath A, Agarwal R, Behera D. A prospective randomized controlled trial on the efficacy of noninvasive ventilation in severe acute asthma. Respir Care. 2010;55:536–43.
    1. Reminiac F, Vecellio L, Heuze-Vourc'h N, Petitcollin A, Respaud R, Cabrera M, et al. Aerosol therapy in adults receiving high flow nasal cannula oxygen therapy. J Aerosol Med Pulm Drug Deliv. 2016;29:134–41.
    1. Perry SA, Kesser KC, Geller DE, Selhorst DM, Rendle JK, Hertzog JH. Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. Pediatr Crit Care Med. 2013;14:e250-6.
    1. Sunbul FS, Fink JB, Harwood R, Sheard MM, Zimmerman RD, Ari A. Comparison of HFNC, bubble CPAP and SiPAP on aerosol delivery in neonates: An in-vitro study. Pediatr Pulmonol. 2015;50:1099–106.
    1. Bachour A, Hurmerinta K, Maasilta P. Mouth closing device (chinstrap) reduces mouth leak during nasal CPAP. Sleep Med. 2004;5:261–7.
    1. Ari A. Aerosol therapy in pulmonary critical care. Respir Care. 2015;60:858–74.
    1. Piccuito CM, Hess DR. Albuterol delivery via tracheostomy tube. Respir Care. 2005;50:1071–6.
    1. Pitance L, Vecellio L, Delval G, Reychler G, Reychler H, Liistro G. Aerosol delivery through tracheostomy tubes: An in vitro study. J Aerosol Med Pulm Drug Deliv. 2013;26:76–83.
    1. Mazela J, Polin RA. Aerosol delivery to ventilated newborn infants: Historical challenges and new directions. Eur J Pediatr. 2011;170:433–44.
    1. Ari A, Harwood RJ, Sheard MM, Fink JB. An in vitro evaluation of aerosol delivery through tracheostomy and endotracheal tubes using different interfaces. Respir Care. 2012;57:1066–70.
    1. Hintz SR. Pharmacology review: Bronchodilator therapy in the preterm infant. Neoreviews. 2003;4:e245-9.
    1. Sosulski R, Abbasi S, Bhutani VK, Fox WW. Therapeutic value of terbutaline in bronchopulmonary dysplasia. Pediatr Pulmonol. 1986;2:269–273.
    1. Gappa M, Gärtner M, Poets CF, von der Hardt H. Effects of salbutamol delivery from a metered dose inhaler versus jet nebulizer on dynamic lung mechanics in very preterm infants with chronic lung disease. Pediatr Pulmonol. 1997;23:442–8.
    1. Diblasi RM. Clearing the mist from our eyes: Bronchodilators, mechanical ventilation, new devices, locations, and what you should know about bias flow. Respir Care. 2010;55:942–6.
    1. Dhand R. Bronchodilator therapy. In: Tobin MJ, editor. Principles and Practice of Mechanical Ventilation. 2nd ed. New York: McGraw-Hill; 2006. pp. 1277–310.
    1. Dhand R. Aerosol delivery during mechanical ventilation: From basic techniques to new devices. J Aerosol Med Pulm Drug Deliv. 2008;21:45–60.
    1. Selroos O, Borgström L, Ingelf J. Use of dry powder inhalers in acute exacerbations of asthma and COPD. Ther Adv Respir Dis. 2009;3:81–91.
    1. Thomas M, Williams AE. Are outcomes the same with all dry powder inhalers. Int J Clin Pract Suppl. 2005;149:33–5.
    1. Fink JB, Rubin BK. Problems with inhaler use: A call for improved clinician and patient education. Respir Care. 2005;50:1360–74.
    1. Boukhettala N, Porée T, Diot P, Vecellio L. In vitro performance of spacers for aerosol delivery during adult mechanical ventilation. J Aerosol Med Pulm Drug Deliv. 2015;28:130–6.
    1. Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care. 2010;55:845–51.
    1. Garner SS, Wiest DB, Bradley JW. Albuterol delivery by metered-dose inhaled in a pediatric high-frequency oscillatory ventilation mode. Crit Care Med. 2000;28:2086–9.
    1. DiBlasi RM, Crotwell DN, Shen S, Zheng J, Fink JB, Yung D. Iloprost drug delivery during infant conventional and high-frequency oscillatory ventilation. Pulm Circ. 2016;6:63–9.
    1. Ari A, Harwood RJ, Sheard MM, Fink JB. Pressurized metered-dose inhalers versus nebulizers in the treatment of mechanically ventilated subjects with artificial airways: An in vitro study. Respir Care. 2015;60:1570–4.
    1. Katzman M, Meade W, Iglar K, Rachlis A, Berger P, Chan CK. High incidence of bronchospasm with regular administration of aerosolized pentamidine. Chest. 1992;101:79–81.
    1. Zitter JN, Maldjian P, Brimacombe M, Fennelly KP. Inhaled Dornase alfa (Pulmozyme) as a noninvasive treatment of atelectasis in mechanically ventilated patients. J Crit Care. 2013;28:218.e1–7.
    1. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, et al. Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Me. 2011;184:561–8.
    1. Lin HL, Fink JB, Zhou Y, Cheng YS. Influence of moisture accumulation in inline spacer on delivery of aerosol using metered-dose inhaler during mechanical ventilation. Respir Care. 2009;54:1336–41.
    1. Delgado A, Chou KJ, Silver EJ, Crain EF. Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med. 2003;157:76–80.
    1. Macfarlane JT, Lane DJ. Irregularities in the use of regular aerosol inhalers. Thorax. 1980;35:477–8.
    1. Newman SP, Millar AB, Lennard-Jones TR, Moren F, Clarke SW. Improvement of pressurized aerosol deposition with Nebuhaler spacer device. Thorax. 1984;39:935–41.
    1. Nebulizer therapy. Guidelines. British Thoracic Society Nebulizer Project Group. Thorax. 1997;52(Suppl 2):S4–24.
    1. Alhaider SA, Alshehri HA, Al-Eid K. Replacing nebulizers by MDI-spacers for bronchodilator and inhaled corticosteroid administration: Impact on the utilization of hospital resources. Int J Pediatr Adolesc Med. 2014;1:26–30.
    1. Wildhaber JH, Dore ND, Wilson JM, Devadason SG, LeSouëf PN. Inhalation therapy in asthma: Nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr. 1999;135:28–33.
    1. Salzman GA, Steele MT, Pribble JP, Elenbaas RM, Pyszczynski DR. Aerosolized metaproterenol in the treatment of asthmatics with severe airflow obstruction. Comparison of two delivery methods. Chest. 1989;95:1017–20.
    1. Colacone A, Afilalo M, Wolkove N, Kreisman H. A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. Chest. 1993;104:835–41.
    1. Kerem E, Levison H, Schuh S, O’Brodovich H, Reisman J, Bentur L, et al. Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. J Pediatr. 1993;123:313–7.
    1. Ros SP. Emergency management of childhood bronchial asthma: A multicenter survey. Ann Allergy. 1991;66:231–4.
    1. Tal A, Pasterkamp H, Leahy F. Arterial oxygen desaturation following salbutamol inhalation in acute asthma. Chest. 1984;86:868–9.
    1. Agent P, Parrott H. Inhaled therapy in cystic fibrosis: Agents, devices and regimens. Breathe (Sheff) 2015;11:110–8.
    1. Nevitt SJ, Thornton J, Murray CS, Dwyer T. Cochrane Database Syst Rev. 2018. Feb, Inhaled mannitol for cystic fibrosis. 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3. Update in: Cochrane Database Syst Rev. 2020 May 1;5:CD008649. PMID: 29424930. PMCID: PMC6491147.
    1. Moraa I, Sturman N, McGuire TM, van Driel ML. Heliox for croup in children. Cochrane Database Syst Rev. 2018 Oct; 29;10(10):CD006822. doi: 10.1002/14651858.CD006822.pub5. PMID: 30371952. PMCID: PMC6516979.
    1. Cruz AT, Cazacu AC, Greer JM, Demmler GJ. Performance of a rapid assay (Binax NOW) for detection of respiratory syncytial virus at a children's hospital over a 3-year period. J Clin Microbiol. 2007;45:1993–5.
    1. Unger S, Cunningham S. Effect of oxygen supplementation on length of stay for infants hospitalized with acute viral bronchiolitis. Pediatrics. 2008;121:470–5.
    1. Lehtinen P, Jartti T, Virkki R, Vuorinen T, Leinonen M, Peltola V, et al. Bacterial coinfections in children with viral wheezing. Eur J Clin Microbiol Infect Dis. 2006;25:463–9.
    1. Al-Ansari K, Sakran M, Davidson BL, El Sayyed R, Mahjoub H, Ibrahim K, et al. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr. 2010;157:630–4.
    1. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118:1774–93.
    1. Guerguerian AM, Gauthier M, Lebel MH, Farrell CA, Lacroix J. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. Am J Respir Crit Care Med. 1999;160:829–34.
    1. Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care. 2005;50:1346–59.
    1. Grieble HG, Colton FR, Bird TJ, Toigo A, Griffith LG. Fine-particle humidifiers. Source of Pseudomonas aeruginosa infections in a respiratory-disease unit. N Engl J Med. 1970;282:531–5.
    1. Sanchis J, Gich I, Pedersen S Aerosol Drug Management Improvement Team (ADMIT) Systematic review of errors in inhaler use: Has patient technique improved over time. Chest. 2016;150:394–406.
    1. Koehorst-Ter Huurne K, Movig K, van der Valk P, van der Palen J, Brusse-Keizer M. The influence of type of inhalation device on adherence of COPD patients to inhaled medication. Eur Respir J. 2013;42:4146.
    1. Dennis JH. Standardization issues: In vitro assessment of nebulizer performance. Respir Care. 2002;47:1445–58.
    1. Rau JL. Practical problems with aerosol therapy in COPD. Respir Care. 2006;51:158–72.
    1. Vassal S, Taamma R, Marty N, Sardet A, d'Athis P, Brémont F, et al. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control. 2000;28:347–51.
    1. Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, et al. Home-use nebulizers: A potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol. 1996;34:584–7.
    1. Saiman L, Siegel J Cystic Fibrosis Foundation. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol. 2003;24:S6-52.
    1. Chew NY, Reddel HK, Bosnic-Anticevich SZ, Chan HK. Effect of mouthpiece washing on aerosol performance of CFC-free Ventolin. J Asthma. 2004;41:721–7.
    1. Stopping the spread of germs [Internet] Cystic Fibrosis Foundation. 2009. [Last accessed 2021 Mar 24]. Available from: .
    1. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health care – Associated pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004;53:1 36.
    1. O’Malley CA, VandenBranden SL, Zheng XT, Polito AM, McColley SA. A day in the life of a nebulizer: Surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. Respir Care. 2007;52:258 62.
    1. American Association for Respiratory Care. AARC Clinical Practice Guideline. Selection of aerosol delivery device. American Association for Respiratory Care. Respir Care. 1992;37:891–7.
    1. Larson T, Gudavalli R, Prater D, Sutton S. Critical analysis of common canister programs: A review of cross functional considerations and health system economics. Curr Med Res Opin. 2015;31:853 60.
    1. Gowan M, Bushwitz J, Watts P, Silver PC, Jackson M, Hampton N, et al. Use of a shared canister protocol for the delivery of metered dose inhalers in mechanically ventilated subjects. Respir Care. 2016;61:1285 92.
    1. Rau JL, Restrepo RD. Nebulized bronchodilator formulations: Unit dose or multi dose. Respir Care. 2003;48:926 39.
    1. Boyce JM, Pittet D Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/ APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51:1–CE4.
    1. Rhinehart E, Friedman MM. Infection Control in Home Care (An Official APIC Publication) Gaithersburg MD: Aspen Publishers, Inc; 2006. Personal protective equipment and staff supplies; pp. 61–9.
    1. Larson EL. APIC guideline for handwashing and hand antisepsis in health care settings. Am J Infect Control. 1995;23:251 69.
    1. Siegel JD, Rhinehart E, Jackson M, Chiarello L Health Care Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: Preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35:S65 164.
    1. WHO Guidelines on Hand Hygiene in Health Care: a Summary [Internet] World Health Organization; 2009. Available from: . Last cited on 2021 Mar 24.
    1. Segal-Maurer S, Kalkut GE. Environmental control of tuberculosis: Continuing controversy. Clin Infect Dis. 1994;19:299–308.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다